Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Sparsentan in Immunoglobulin A Nephropathy
NCT03762850Phase 3Completed
- Sponsor
- Travere Therapeutics
- Start
- Dec 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of sparsentan in immunoglobulin A nephropathy (IgAN), sponsored by Travere Therapeutics. Started Dec 2018; status: completed.
02
Drugs
sparsentan
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03762850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762850.